Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency
- 31 December 2009
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 124 (6), 1303-1310.e4
- https://doi.org/10.1016/j.jaci.2009.08.007
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- New promise and hope for treating hereditary angioedemaExpert Opinion on Investigational Drugs, 2008
- New treatments addressing the pathophysiology of hereditary angioedemaClinical and Molecular Allergy, 2008
- 8. Hereditary angioedemaJournal of Allergy and Clinical Immunology, 2008
- New therapies for hereditary angioedema: Disease outlook changes dramaticallyJournal of Allergy and Clinical Immunology, 2008
- Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitorJournal of Allergy and Clinical Immunology, 2007
- Fifty years of research on the plasma kallikrein-kinin system: From protein structure and function to cell biology and in-vivo pathophysiologyThrombosis and Haemostasis, 2007
- Homozygous C1 inhibitor deficiency: The conclusion of a long searchJournal of Allergy and Clinical Immunology, 2006
- Bradykinin receptor ligands: therapeutic perspectivesNature Reviews Drug Discovery, 2004
- Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyondJournal of Allergy and Clinical Immunology, 2004
- Transcription Factor Nuclear Factor κB Regulates the Inducible Expression of the Human B1 Receptor Gene in InflammationOnline Journal of Public Health Informatics, 1998